Skip to main content
SpringerLink
Log in

Vaccination préventive anti-papillomavirus État des lieux et perspectives

  • Dossier
  • Published:
Oncomagazine

Résumé

Malgré le succès considérable enregistré par le dépistage précoce pour la prévention du cancer du col utérin, le frottis n’a pas bénéficié de tous les espoirs auxquels on pouvait s’attendre pour réduire à une large échelle son incidence. Un vaccin prophylactique, pour se protéger des lésions précancéreuses et cancéreuses HPV associées, devrait sauver des vies, réduire les interventions coûteuses et aurait un bénéfice individuel et collectif non négligeable. L’efficacité vaccinale n’est démontrée que chezles jeunes filles naïves jamais exposées aux virus et seulement pour les lésions associées aux types viraux du vaccin.

Les recommandations françaises stipulent pour le vaccin quadrivalent disponible que la vaccination devra être généralisée pour toutes les jeunes filles de quatorze ans avec un rattrapage jusqu’à vingt trois ans pour les vierges ou moins d’un an après les premiers rapports.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Monsonego J. Infections à papillomavirus, état des connaissances, pratiques et prevention vaccinale. J. Monsonego, Springer Ed, Paris 2006

    Google Scholar 

  2. Koutsky LA, Ault KA, Wheeler CM et al. (2002) Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 21:1645–5.

    Article  Google Scholar 

  3. Villa LL, Costa RL, Petta CA, et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 5:271–8

    Article  Google Scholar 

  4. Villa LL, Costa RL, Petta CA, et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 11:1459–66

    Article  Google Scholar 

  5. Harper DM, Franco EL, Wheeler C, GlaxoSmithKline, et al. (2004) HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 9447:1757–65

    Article  Google Scholar 

  6. Harper DM, Franco EL, Wheeler CM, HPV Vaccine Study group, et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 9518:1247–55

    Article  Google Scholar 

  7. Mao C, Koutsky LA, Ault KA, et al. (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 1:18–27

    Google Scholar 

  8. Garland SM. (2007) Quadrivalent vaccine against papillomavirusto prevent anogenital diseases. N Engl J Med 356:1928–41

    Article  PubMed  CAS  Google Scholar 

  9. Koutsky L. (2007) Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. N Engl J Med 356:1915–27

    Article  Google Scholar 

  10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. (2007) Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 19:1928–43

    Article  Google Scholar 

  11. FUTURE II Study Group. (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 19:1915–27

    Article  Google Scholar 

  12. Joura EA, Leodolter S, Hernandez-Avila M, et al. (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 9574:1693–702

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynécologue, Paris

    Joseph Monsonego

Authors
  1. Joseph Monsonego
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Monsonego, J. Vaccination préventive anti-papillomavirus État des lieux et perspectives. Oncomagazine 1, 8–12 (2007). https://doi.org/10.1007/BF03165569

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03165569

Mots clés

Search

Navigation